Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors

Patent metadata

Field	Value
Publication number	US-9670191-B2
Application number	US-201514688207-A
Country	US
Kind code	B2
Filing date	Apr 16, 2015
Priority date	Mar 27, 2006
Publication date	Jun 6, 2017
Grant date	Jun 6, 2017

Abstract

The present invention provides compounds of the formula (I), or the pharmaceutically acceptable salts thereof, wherein G, W, R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the specification. Further objects of the invention are processes and intermediates for the preparation of the compounds of the formula (I), pharmaceutical compositions comprising them and methods for treating cell proliferative disorders. As a matter of fact, the compounds of the formula (I) are useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

First claim

The invention claimed is:

1. A method for treating cell proliferative disorders caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a compound which is 5-(2-amino-pyrimidin-4-yl)-2-(2,3-dimethyl-phenyl)-1H-pyrrole-3-carboxylic acid amide, or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 , wherein the cell proliferative disorder is selected from the group consisting of cervical cancer, colon cancer, ovarian cancer, pancreatic cancer, breast cancer, ductal breast cancer, epidermal cancer, lung cancer, large cell lung cancer, squamous cell lung cancer, small cell lung cancer, non-small cell lung cancer, medullary thyroid cancer, papillary thyroid cancer, astrocitoma, neuroblastoma, glioblastoma, gliosarcoma, melanoma and osteosarcoma.

3. The method according to claim 1 , wherein the cell proliferative disorder is selected from the group consisting of colon cancer, pancreatic cancer, breast cancer, ductal breast cancer, large cell lung cancer, squamous cell lung cancer, small cell lung cancer, non-small cell lung cancer, medullary thyroid cancer, papillary thyroid cancer, neuroblastoma, glioblastoma, gliosarcoma, melanoma and osteosarcoma.

4. The method according to claim 3 , wherein the cell proliferative disorder is selected from the group consisting of colon cancer, pancreatic cancer, breast cancer, large cell lung cancer, squamous cell lung cancer, small cell lung cancer, non-small cell lung cancer, medullary thyroid cancer, papillary thyroid cancer, neuroblastoma, glioblastoma, and melanoma.

5. The method according to claim 4 , wherein the cell proliferative disorder is selected from the group consisting of colon cancer, non-small cell lung cancer, medullary thyroid cancer, papillary thyroid cancer, neuroblastoma, glioblastoma, and melanoma.

6. The method according to claim 5 , wherein the cell proliferative disorder is selected from the group consisting of colon cancer, non-small cell lung cancer, neuroblastoma, glioblastoma, and melanoma.

7. The method according to claim 6 , wherein the cell proliferative disorder is selected from the group consisting of colon cancer and non-small cell lung cancer.

8. The method according to claim 1 further comprising subjecting the mammal in need thereof to radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent.

9. The method according to claim 1 wherein the mammal in need thereof is a human.

10. A method for treating cell proliferative disorders caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of pharmaceutical composition comprising a compound which is 5-(2-amino-pyrimidin-4-yl)-2-(2,3-dimethyl-phenyl)-1H-pyrrole-3-carboxylic acid amide, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, carrier or diluent.

11. The method according to claim 10 , wherein said pharmaceutical composition comprises from about 10 mg to about 1000 mg of said 5-(2-amino-pyrimidin-4-yl)-2-(2,3-dimethyl-phenyl)-1H-pyrrole-3-carboxylic acid amide, or a pharmaceutically acceptable salt thereof.

12. The method according to claim 11 , wherein said pharmaceutical composition is in the form of a tablet, a capsule, a solution, or a suspension.

13. The method according to claim 12 , wherein said pharmaceutical composition is in the form of a tablet or capsule.

14. The method according to claim 13 , wherein said pharmaceutical composition is in the form of a tablet.

15. The method according to claim 14 , wherein said pharmaceutical composition is in the form of a capsule.

16. The method according to claim 10 , wherein the cell proliferative disorder is selected from the group consisting of cervical cancer, colon cancer, ovarian cancer, pancreatic cancer, breast cancer, ductal breast cancer, epidermal cancer, lung cancer, large cell lung cancer, squamous cell lung cancer, small cell lung cancer, non-small cell lung cancer, medullary thyroid cancer, papillary thyroid cancer, astrocitoma, neuroblastoma, glioblastoma, gliosarcoma, melanoma and osteosarcoma.

17. The method according to claim 16 , wherein the cell proliferative disorder is selected from the group consisting of colon cancer, non-small cell lung cancer, medullary thyroid cancer, papillary thyroid cancer, neuroblastoma, glioblastoma, and melanoma.

18. The method according to claim 17 , wherein the cell proliferative disorder is selected from the group consisting of colon cancer and non-small cell lung cancer.

19. The method according to claim 10 further comprising subjecting the mammal in need thereof to radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent.

20. The method according to claim 10 wherein the mammal in need thereof is a human.

Assignees

• Nerviano Medical Sciences Srl

Inventors

• Vanotti Ermes
• Caldarelli Marina
• Cirla Alessandra
• Forte Barbara
• Ermoli Antonella
• Menichincheri Maria
• Pillan Antonio
• Scolaro Alessandra

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title